As previously reported, on February 12, 2016, in connection with our merger with Protagenic Therapeutics, Inc., the holders of our Series A Convertible Preferred Stock, par value $0.000001 per share (the “ Series A Preferred Stock ”), exchanged all of the issued and outstanding Series A Preferred Stock for an aggregate of 297,468 shares of Series B Convertible Preferred Stock, par value $0.000001 per share (the “ Series B Preferred Stock ”). Accordingly, no shares of Series A Preferred Stock remain issued and outstanding.

On April 1, 2016, we filed a Certificate of Elimination of the Series A Convertible Preferred Stock of Atrinsic, Inc. (the “ Certificate of Elimination ”) with the Secretary of State of the State of Delaware to eliminate our Series A Preferred Stock, all of the outstanding shares of Series A Preferred Stock having been exchanged for Series B Preferred Stock.  The Certificate of Elimination, effective upon filing, had the effect of eliminating from our Amended and Restated Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations, Powers, Preferences and other Rights of Preferred Stock and Qualifications, Limitations and Restrictions of Series A Convertible Preferred Stock for Atrinsic, Inc. (the “ Series A Certificate of Designations ”) with respect to such series, which was previously filed by us with the Secretary of State on July 9, 2013.  Accordingly, the 4,600,000,000 shares of Series A Preferred Stock previously reserved for issuance under the Series A Certificate of Designations resumed their status as authorized but unissued shares of undesignated preferred stock of Atrinsic, Inc. upon filing of the Certificate of Elimination.

A copy of the Certificate of Elimination is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 5.03.